Claremont Colleges

Scholarship @ Claremont
CMC Senior Theses

CMC Student Scholarship

2016

Identification of Functional Single Nucleotide
Polymorphisms Associated with Breast Cancer
Based on Chromatin Modifications
Laura E. Hayward
Claremont McKenna College

Recommended Citation
Hayward, Laura E., "Identification of Functional Single Nucleotide Polymorphisms Associated with Breast Cancer Based on
Chromatin Modifications" (2016). CMC Senior Theses. Paper 1312.
http://scholarship.claremont.edu/cmc_theses/1312

This Open Access Senior Thesis is brought to you by Scholarship@Claremont. It has been accepted for inclusion in this collection by an authorized
administrator. For more information, please contact scholarship@cuc.claremont.edu.

Identification of Functional Single Nucleotide Polymorphisms Associated with Breast
Cancer Based on Chromatin Modifications

A Thesis Presented
by

Laura E. Hayward

To the Keck Science Department
Of Claremont McKenna, Pitzer, and Scripps Colleges
In partial fulfillment of
The degree of Bachelor of Arts

Senior Thesis in Biology
April 24, 2016

Table of Contents
Abstract…………………………………………………………………………………...pg 3
Introduction……………………………………………………………………………pgs 3-8
Methodology………………………………………………………………………….pgs 8-10
Results……...………………………………………………………………………..pgs 10-15
Discussion….………………………………………………………………………..pgs 15-19
Literature Cited……………………………………………………………………....pgs 20-22

2

Abstract
Breast cancer affects 1 in 8 women and can be deadly; yet when detected early
enough it is often treatable. Thus, early detection of breast cancer is imperative to save lives.
The success of early detection depends, in part, on being able to stratify risk. A new
approach to determining risk involves identifying genetic variants that alter an individual’s
risk for developing breast cancer. This thesis identified key functional candidates involved in
breast cancer development, some of which have been verified by other studies. For a few of
the functional candidates, further research needs to be done in order to determine the
biological significance they play in the development of breast cancer. The functional
candidates were identified by comparing SNPs in Linkage Disequilibrium with high risk
SNPS—determined by GWAS—using histone modification markers to identify functional
genomic elements in breast cell lines. The results yielded three top tier candidates and
multiple second tier candidates. Further research should be done in order to assess the risk
involved with these variants and the underlying biological mechanism. As genetic testing
becomes more accessible to the public, the identification and understanding of these high risk
variants will be an essential tool in preventing and treating breast cancer.

Introduction
According to the Centers for Disease Control and Prevention, approximately 8
million people die from cancer each year.1 It is a disease that affects not only the patient
diagnosed, but also the families of the patients. In addition to the emotional component,
cancer often affects family members physically, as many cancers have a significant genetic
and familial component. Individuals with a first degree relative who has been diagnosed with
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breast cancer have a two fold increase in risk for developing breast cancer themselves.1
Although these statistics are disheartening, one third of all cancer related deaths can be
prevented.1 Cancer prevention includes cancer screenings for individuals at a high risk for
developing cancer.1 Given the large genetic component to cancer and the importance of
screening in prevention, it is crucial to determine the specific genetic markers associated with
the disease.
Certain highly penetrant genes associated with breast cancer have been previously
identified in a multitude of studies.2 However, highly penetrant genes associated with breast
cancer present in the following genes: BRCA1/2, TP53, ATM,CHEK2, BRIP1, PALB2 and
PTEN, account for less than 25% of the genetic risk of cancer, suggesting that the remaining
genetic component of cancer risk is due to the combination of many common genetic
variants.2 Currently, there has been a shift from looking for more of these highly penetrant
genes towards identifying single nucleotide polymorphisms (SNP) in specific regions that
increase risk for developing cancer.2 Below are a few specific studies that illustrate the
importance of examining individual SNPs in determining an individual’s risk of developing
cancer.
According to Pharaoh et al.’s (2007) study on 120 variations associated with breast
cancer, multiple alleles contribute to familial risk of development of cancer, as is understood
in the polygenic model of cancer. In this study, 710 SNPs were examined in 4,400 breast
cancer cases and 4,400 controls.3 The authors identified multiple SNPs that are associated
with breast cancer; however, each candidate is likely responsible for a slight increase in risk.3
Although risk associated with individual single nucleotide polymorphisms are small, an
accumulation of these SNPs could significantly increase a patient’s risk for cancer.3 Chan et
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al. (2012) reported that patients with greater than 6 or more high risk alleles had a 90%
increased risk of developing breast cancer.4 Their study consisted of 1291 patients with
breast cancer of southern Chinese descent.4 One of the high risk SNPs identified was
rs2981579, a SNP examined in this thesis. Similarly, Easton et al. conducted a genome wide
association study in 2007, identifying five novel loci associated with increased breast cancer
susceptibility.2 In this study, 4,398 breast cancer cases and 4,316 controls were tested in the
first stage.2 Discovering these high risk SNPS are critical in determining a patient’s overall
lifetime risk for developing breast cancer.
The studies mentioned above are examples of Genome Wide Association Studies
(GWAS) where the purpose of these studies is to “identify genetic risk factors for diseases
that are common in the population”.5 GWAS examine variations across the human genome
and identify correlations between individual variants and disease. Eventually, the results of
Genome Wide Association Studies may improve screening prevention and early detection.
Most SNPs identified by GWAS as strongly associated with disease have no known
biological effect.5 Only a small number of these SNPs have been shown to directly change
biological function.5 These are the important SNPs to identify, also known as the functional
SNPs. The mechanisms behind which these SNPs may change biological function include
changes to mRNA, DNA-binding affinities, and modifications to protein sequences.5 The
reason for this discrepancy between a SNPs association with disease and its actual effect on
biological function is due to a concept known as linkage disequilibrium. Linkage
Disequilibrium (LD), as defined by Bush et al. (2012), is a “property of SNPs on a
contiguous stretch of genomic sequence that describes the degree to which an allele of one
SNP is inherited or correlated with an allele of another SNP within a population.”5 Meaning,
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the marker or tag SNP that is initially associated with an increased risk for developing a
disease might not be the functional SNP contributing to disease. A tag SNP represents a
larger number of SNPs in high disequilibrium that is highly associated with a disease, such as
cancer.5 In cases where there is high linkage disequilibrium with the functional SNP, it is
possible that the tag SNP may be genotyped and statistically associated with the SNP, but not
responsible for change in biological function. In GWAS studies, linkage disequilibrium is
used to screen many variants at once with a small number of markers capturing the variants
in the region.5 The presence of linkage disequilibrium limits GWAS studies because it is
impossible to know whether the statistically significant SNP has an indirect association or
whether it is the functional SNP, with a direct association.5 In this thesis, the location of the
breast-cancer causing functional SNPs will be determined by comparing the SNPs in LD
with the tag SNP to histone modification data in breast cell lines.
Histone modification is a key component of epigenetic regulation, and it is epigenetic
abnormalities coupled with genetic alterations that are responsible for disease.6 Epigenetics
defined as changes, not affecting the actual DNA sequence, in gene expression that are
heritable.6 Since histone modifications are important markers of function it is important
aspect to examine when determining which SNP affects function.7 If a SNP is associated
with a region affecting histone modification or regulation it is possible that it is a functional
SNP. Histone modifications, more specifically, H3K4me1 and H3K27ac have been
previously discovered at nucleosomes near enhancer elements.8 According to Heintzman et
al. (2009), enhancers have histone modification configurations that are cell specific.9 The
actual role that histone modifications place in changing enhancer function has been debated
and the conclusions are controversial. Thus, we cannot conclude that these SNPS located in
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regions associated with histone modifications regions directly affect enhancer function;
however, it can act as a marker for functional elements. According to Mcvicker et al., the
exact role of non-coding regulatory sequences in affecting disease phenotypes is not wholly
understood and is a topic of interest that should be further studied.7 Although our knowledge
on the mechanism behind histone modification’s involvement in cancer development is
limited, it is clear that histone modifications are markers that can be used to find functional
elements. According to Jones and Baylin (2007) review on the epigenomics of cancer, an
important characteristic of cancer is changes in patterns of gene expression.6 Since alterations
in enhancer elements, which impact gene expression, affect the development of cancer,
histone modifications are good markers to use in looking at SNPs that may increase risk of
developing cancer. By examining the relationship between potential functional SNP
candidates and high density of histone modifications, the actual functional SNP can be
identified. For example, if a SNP is located in the same region of a gene that is associated
with a histone modifications it is likely that this SNP may be responsible for biological
change in function.
A lot of genome wide association studies have used populations from European
descent in their research. Due to the fact that in different populations there are differing
Linkage Disequilibrium patterns, highly associated SNPs in one population may not
correspond to a high associative risk in another population.5 In the case of this thesis, the
population examined is that of European descent. So in looking at the SNPs below, the
findings will only be helpful or indicative of a potential increased risk in strictly European
populations. Further studies will need to be done to determine the high risk SNPs in other
populations.
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In summary, there are a multitude of unknown genetic variants known as SNPs that
are likely to increase an individual’s risk of developing breast cancer. Given that cancer
affects so many people and is often treatable when detected early, determining these high risk
variants can save lives. However, determining the exact functional SNP responsible for
affecting biological function is difficult due to linkage disequilibrium. Thus, this thesis will
compare SNPs—that are in LD with the high risk SNPs associated with breast cancer—with
histone modification markers in breast cell lines. Looking forward, if the functional SNPs
involved in breast cancer can be identified, eventually medical professionals can use this
information in order to determine an individual's risk for developing breast cancer and
potential prevent late detection in patients.

Methodology
In order to determine the mechanism behind highly associated SNPs, previously
collected data located in the UCSC genome browser were compared to breast cell tracks
containing non-coding region information from the Epigenomics Roadmap.10 Initially, the
GWAS catalog was used to locate single nucleotide polymorphisms that have been
previously associated with breast cancer. The catalog provided rs2981579 as the SNP with
the lowest p value (2x10^-170).11 The catalog also provides the SNPs with the highest odds
ratio, which is important to look at as it shows the SNP that has the highest risk with breast
cancer. SNP rs594206 had the highest odds ratio with a ratio of 36.3.11 This means that
individuals who have this SNP have a 36.3 higher chance of getting breast cancer than the
average individual.12 Odds ratio is important to look at as it gives us an idea of what are the
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chances of an individual without the variant have of developing cancer in comparison to the
odds of an individual with the variant of developing cancer.12
Once these SNPs were identified, the SNPs were entered into the web program
known as rAggr and LD list generated questions regarding the SNPs population were
answered.13 In the two SNPs examined, the population consisted of individuals from
European descent. The r squared value ranged from 0.5 and 1.0, meaning that only values
that had a r-squared of 0.5 or above were included in the file. Once submitted, the bed files of
all the SNPs in LD with the tag SNP were obtained. This step was repeated for both tag
SNPS: rs2981579 and rs594206.
The resulting data sets were added as custom tracks on the genome browser at UCSC.
Once the tracks were added the location of the SNPs were initially visually compared with
the layered H3K27AC track containing regulatory elements from 7 cell lines from ENCODE.
Observations were made in order to determine if there were any SNPs in LD that
corresponded in a peak with the layered H3K27AC track containing regulatory elements
from 7 cell lines from ENCODE. The genome browser Epigenomics Roadmap data was then
accessed in order to add additional tracks indicating CpG and MRE methylation sites.10 Once
the cell tracks were loaded into the genome browser and zoomed in on the location, the peaks
were detected in some of the tissues. Tracks containing information on specific breast cell
lines, as can be seen in Table 1, were added to the genome browser at UCSC.
After adding the tracks from breast cells lines, the SNPs in LD were compared to the
cell lines. Through visual observation it became clear which SNPs were located in a region of
high density in the specific breast cell tracks. Once the visual comparisons were made,
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further research on these SNPS, via PubMed, was completed in order to determine if
previous research could shed light on the function of the identified SNP.
The process mentioned above was completed for both: rs2981579 and rs594206.

Table 1. Description of tracks based on cell line, type of histone modification marker, ID
number, and location where information was obtained

Cell Line

Histone Modification
Marker

Location

ID

Breast vHMEC

H3K4me3

REMC/UCSF

35

Breast vHMEC

H3k4me1

REMC/UCSF

35

Breast Myoepithelial

H3k4me1

REMC/UCSF

80

Breast Myoepithelial

H3K4me1

REMC/UCSF

66

Breast Myoepithelial

H3K4me3

REMC/UCSFUB

80

Breast Myoepithelial

H3K4me3

66
REMC/UCSF

7 Cell Lines

Layered H3K27AC

NA
Encode

Results
The figures below will assist in explaining the results obtained in this study. The
haploytpe blocks, as can be seen below, are measured with color, where black corresponds to
an r-squared valued of 1 and grey corresponds to an r-squared value of 0.5.
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Fig 1. Haplotype blocks for rs2981579 containing all the SNPs in the
area bounded by the two farthest away SNPs with an r2 value >0.2.

Fig 2. Haplotype blocks for rs2981579 containing SNPs in LD with
and r2 >0.5.
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Fig 3. Haplotype blocks for rs594206 containing all the SNPs in the
area bounded by the two farthest away SNPs with an r2 value >0.2.

Fig 4. Haplotype blocks for rs594206 containing SNPs in LD with
and r2 >0.5.
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Fig 5. UCSC Genome Browser view of SNPs in LD with rs594206 indicated. ChIPseq tracks for enhancer histone markers are Breast Myoepithelial Cells (BMC)
H3K4me1 80, Breast Myoepithelial Cells (BMC) H3K4me1 66, Breast Myoepithelial
Cells H3K4me1, and Breast Myoepithelial Cells H3K4me3 from the REMC/UCSF.

Fig 6. UCSC Genome Browser view of SNPs in LD with rs2981579 indicated. ChIPseq tracks for enhancer histone markers are Breast vHMEC H3K4me1, Breast
vHMEC H3k4me3, Breast Myoepthelial Cells H3k4me1, Breast Myoepithelial Cells
H3k4me3 from REMC/UCSF.
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After the visual comparison of the SNPs in LD with rs594206, rs594132 stood out as
the primary candidate as the functional SNP contributing to high risk associated with
rs594206 (Figure 5). SNP rs594132 mutation from A to C is located where there is a high
density in the Chip-seq tracks for enhancer histone marks in the following cell lines: Breast
Myoepithelial Cells (BMC) H3K4me1, Breast Myoepithelial Cells (BMC) H3K4me1, Breast
Myoepithelial Cells (BMC) H3k4me1, and Breast Myoepithelial Cells (BMC) H3K4me3 80
from the REMC/UCSF. Both rs635766 and rs643196, SNPs associated with rs594206, align
with a slightly dense area of the Chip-seq tracks for enhancer histone marks within Breast
Myoepithelial Cells H3K4me1 track, suggesting that these are secondary functional
candidates. SNP rs594206 may be a potential candidate has it is located where there are
slightly high peaks in the track for enhancer histone markers in Breast vHMEC H3K4me1
and Breast Myoepithelial Cell H3K4me1 Signal From REMC/UCSF-BUC track (Figure 5).
Lastly, SNP rs656323 aligns with a high density of H3K4me1 and H3K4me3 signaling and
histone modifications in breast cell lines (Figure 5).
In comparing the SNPs in LD with rs2981579, SNP rs10736303 corresponded with a
significantly high peak in the breast vHMEC H3K4me3 Histone Modification by ChIP-Seq
Signal from REMC/UCSF track as well as with the layered H3k27AC marker often found
near active regulatory elements on 7 cell lines from Encode track (Figure 6). Secondly, SNP
rs3135718 is in the same location has a very strong peak in the Breast Myoepithelial Cells
H3K4me3 Signal from REMC/UCSF-BUC track (Figure 6). Both SNPs 10736303 and
rs3135718 are top tier functional candidates as they follow patterns of an enhancer that
correspond with high peaks in regulatory regions of breast cell lines. These two SNPs are the
top candidates for potential being the functional SNP in LD with rs2981579. Additionally,
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there are two other SNPs that follow the pattern of second tier candidates. SNP rs1078806 is
located in a region of the Breast vHMEC H3K4me1 Signal from REMC/UCSF-UBC track
with a peak (Figure 6). SNP rs2981582 corresponds with a peak in the Breast Myoepithelial
Cells H3K4me1 Histone Modification by ChIP-Seq Signal from REMC/UCSF track (Figure
6). Both rs1078806 and rs2981582 are second tier candidates based on the heights and
number of peaks they are closely located near.

Discussion
As mentioned above, SNP rs594132 aligns with a high density of H3K4me3 histone
modifications in breast cell lines. Unfortunately, previous studies reveal very little about the
SNPs in LD with rs594132. Chung et al. (2013) found that rs594132 to be strongly
associated with chemotherapy induced alopecia in 880 breast cancer patients.14 However, this
result is not significantly related to my topic of interest. This lack of information suggests
that further studies should look at the functionality of these SNPs and the potential causal
role they may play in the development of breast cancer.
A few of the candidates in LD with rs2981579, as mentioned above, have been
associated with breast cancer risk in previous studies. In Kim et al. (2012) study identifying
breast cancer risk variants in 6,222 Korean breast cancer patients and 5,897 Korean
individuals acting as controls, rs10726303 was confirmed to have a strong association with
breast cancer.15 However, it was not the most heavily associated SNP identified to increase
risk.15 These results corroborate the findings mentioned above, confirming the possibility that
rs10736303 is in fact a top candidate for being the functional SNP. In a Russian population,
examined by Boyarskikh (2009), rs3135718 was found to have a stronger association with
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breast cancer than a previously identified SNP, suggesting that this SNP could be a causative
variant.16 This study included 766 cases and 665 control woman from Siberia, Russian
Federation to look at the possible risk variants causing breast cancer within the FGFR2
gene.16 Similar to the last study, these results corroborate the findings we see in this thesis.
Suggesting that rs3135718 is a potential functional variant playing a role in increasing risk of
developing breast cancer. Even the second tier candidates are associated with previous
findings. According to Anderson et al. (2013) study on breast cancer susceptibility and
potential modifications by post-menopausal hormonal therapy, rs1219648 is associated with
breast cancer and it is unclear whether these effects are modified by post-menopausal
hormonal therapy use.17 Similarly, SNP rs2981582 has been previously shown to be a
candidate SNP for the development of breast cancer in multiple populations.18 This
association was mentioned in a study examining 81 normal breast tissues from Caucasian
American, African American, and other unknown backgrounds.18 According to this study, it
is unclear whether this correlation is present in breast cancer cell tissues or simply normal
breast cell tissues. The results of the study were inconclusive.
In summary, it is clear that there are a few functional candidates that could play a
biological role and increase an individual’s risk of developing cancer. Given the location of
the SNP in correspondence with histone modification marks it seems probable that rs594206
is a top candidate involved with enhancers affecting gene regulation and biological function.
Similarly, based on the results mentioned above, SNPs rs10736303 and rs3135718 in LD
with rs298157 are top tier functional candidates, which has been confirmed by their
association with breast cancer in previous studies. The second tier candidates, rs1219648 and
rs2981582, in LD with rs298157 have been shown to have an association with breast cancer
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in studies. The candidate functional SNPs in LD with rs298157, even the second tier
candidates, have been found to be associated with breast cancer in previous studies.
However, there is more research that needs to be done in examining the under studied
functional candidates that are in LD with rs594206.
Ultimately, discoveries made through GWAS studies allow medical professionals to
determine, which individuals are at a significantly higher risk than the general public for
various disease, creating personalized and preventative care for patients.5 This information
gathered in GWAS studies is not only used in predicting who is at higher risk for developing
breast cancer, but it can be utilized in creating new pharmacologic therapies.5 Similarly,
dosing for existing pharmacologic therapies is affected by genes.5 In understanding a
patient’s genetic variations, the patient’s ability to respond to certain drugs and the
appropriate dosage can be determined.
When thinking about the implications of these Genome Wide Association Studies it is
important to understand the common disease common variant hypothesis. The common
disease common variant hypothesis is, “that common disorders are likely influenced by
genetic variation that is also common in the population.”5 This hypothesis ordinates from the
fact the penetrance for any single variant that may be involved in a common disease is
small.5 Combined with the fact that common diseases frequently show high heritability,
disease susceptibility for these common diseases may therefore be determined by many
variants.5 In order to truly determine the risk of an individual an examination of multiple
variants is required.
Due to the implications of this hypothesis, more studies are necessary to be able to
improve risk estimates that are based on the contribution of many individual variants. Yet at
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some point risk estimates need to help identify the point at which a patient’s risk is high
enough to take preventative measures. Although there are non-invasive screening measures
(MRIs and mammograms) the decision to have a mastectomy to prevent breast cancer is an
incredibly important choice. How strong must risk be to warrant the recommendation for
mastectomy? The answer could be individualized; however, there needs to be data to help
women even consider a prophylactic mastectomy. According to Janssen and Dujin (2008),
the predictive value of common diseases based on multiple genetic variants is limited.19 Not
enough susceptibility variants have been identified. In order to improve the predictive value
of the risk associated common variants, studies must further identify high-risk variants
associated with common diseases, such as breast cancer.
Looking at an individual’s genome, for high risk variants is an example of
personalized medicine. In general, personalized medicine utilizes information from an
individual patient’s genetic background and biological features to treat a patient, ensuring
that the patient’s healthcare is fitted to their specific needs.14 Quantifying high risk variants
will further the field of personalized medicine and hopefully positively change the way that
we understand complex multifactorial etiology.14 However, universal personalized medicine
is only a possibility if it is not available to the public. Given the implications of CDCV
hypothesis, 500,000 to a million common SNPs would need to be genotyped for each
individual, who is of European descent, in order to determine risk levels for a common
disease for every individual.5 For this to be feasible, genotyping technologies need to be very
cost-effective. Fortunately, the current chip-based technologies are likely to be replaced by
new inexpensive technologies.5iWith these decreases in cost, using genetic variants to assess
risk of breast cancer in individuals can become a reality.
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The top functional candidates identified earlier in this thesis may play a causal role in
the development of breast cancer. Hopefully, with further research in this area, and
specifically looking at these SNPS, the use of these variants in assessing breast cancer risk
can be determined. Eventually this information should be utilized to accurately ascertain the
individual's risk of developing breast cancer and assist in preventing this disease that
negatively affects so many individuals and families across the world.
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